

Sprott Equity Research

			07 July 2021
Ticker: SKE CN	SCPe cash: C\$85m	Project: Eskay Creek	
Market cap: C\$858m	Price: C\$13.82/sh	Country: Canada, BC	
RECOMMEND. (unc): BUY	TARGET (unc): C\$17.20/sh	RISK RATING: HIGH	

Today's results from Snip are impressive, with 4.4m @ 110g/t and also 3.8-4.7m @ 30-45g/t that continue to point to big ounce additions here from various assorted drilling. Even better is that many of these holes hit high-grade veins missed by previous operators, with today's vein clusters immediately adjacent to existing development. With the pro-forma cash of ~\$85m in the treasury to drill here now, perhaps there is something much bigger than a subsidiary blending source and >50koz pa. Also, we note a potential buyback play at hand, HOC can earn 60% by spending 2x SKE spend, (\$16m spend by 2018 + since) expiring in 4Q21. We **maintain our BUY rating and C\$ 17.20/sh PT based on a 0.8xNAV**_{5%-1850-24}. This includes 2.7Moz of Eskay Creek resources outside our modelled 3Moz AuEq mining inventory at an attributed US\$50/oz. In our view, the premium is warranted given the potential bump to >400koz pa with Snip / historic waste / satellites, all in a tier 1 jurisdiction. Exploration should now proceed in parallel with the ~1Q22 FS where we would look for payability. Thereafter we think the recent Tahltan investment bodes well for cooperative permitting, which could see build start before the 2024 base case.





Source: Skeena

Footwall drilling at Snip returns 4.4m @ 110g/t from new high-grade vein clusters

Results from the Phase 3 infill and exploration program at Snip highlighted **4.4m** @ **110g/t**, **4.75m** @ **46.9g/t** and **3.8m** @ **58.5g/t** intersected only metres into the hole collared from the 412 level underground drift in the FW zone. This new mineralized zone is open for expansion up-dip 25m, >100 m down-dip and 40m to the west. Other highlights include **3.8m** @ **30.7g/t**, **4m** @ **33.6g/t** and **4.5m** @ **48.4g/t**.

Why we like Skeena Resources

- Large high-grade open pit with SCPe >500koz upside potential in coming 12-18M
- Shift in market dynamics allows concentrate sales for lower capex
- Optionality from high-grade Snip mine nearby to blend concentrate or add ounces
- Catalyst heavy with drilling, metallurgy, PFS and DFS in coming 18M

Catalysts

- CY21: Regional drilling
- 2Q21: Permitting update
- 1Q22: BFS including expanded resource



Brock Salier (London) M: +44 7400 666 913 <u>bsalier@sprott.com</u> Justin Chan (London) M: +44 7554 784 688 <u>ichan@sprott.com</u> Brandon Gaspar (Toronto) M: +1 437 533 3142 <u>bgaspar@sprott.com</u> Eleanor Magdzinski (Toronto) M: +1 705 669 7456 <u>emagdzinski@sprott.com</u>

Equity Research

Ticker: SKE CN	•	mkt cap:			•	Project PNAV today:	0.67x C\$20.62/sł		Asset: Country:	Eskay Cree	
Author: B Salier/ B Gaspar	Kec / U.	8xNAV P		\$17.2/511		1xNAV _{1Q21} FF FD:	C320.02/SI	I	country:	Canada: BO	
Commodity price	CY18A	CY19A	CY20E	CY21E	CY22E	Resource / Reserve	AuEq (koz	z)	AuEq (g/1	t)	
Gold price	1,850	1,850	1,850	1,850	1,850	Pittable resource	5425koz		4.17g/t		
SOTP project valuation*						Underground resource	224koz		5.41g/t		
		C\$m	O/ship	NAVx	C\$/sh	Snip	646koz		13.60g/t		
Ungeared proj. @ build start (2Q.	22)	1,444	100%	1.00x	20.32	Funding: uses	0000		Funding:		0000
Cash 1Q21 + raise		85	100%	1.00x	1.20	PFS capex		SCPe 1Q21			C\$32m
Cash from options	100 F O /	10	100%	1.00x	0.14	SCPe G&A to 1st Au + ABX \$	C\$15m			1Q21 raise	
Eskay Ck resources ex reserve @L	-5\$50/0Z	137	100%	1.00x	1.93	SCPe pre-production expl'n	C\$11m			0% gearing	
Snip (US\$75/oz)		61	100%	1.00x	0.86	SCPe finance costs + wkg cap	C\$69m	Mine build		30% prem.	
Asset NAV5% C\$1850/oz		1,737		N/F 001	24.5	Total uses			lot	al proceeds	
*Shares diluted for options but n Asset value: 1xNPV project (4V5 _{%1} Q21	0.61x	*Cash from options expiring pre first	pour			Buffer	C\$3m
Project NPV (C\$m)*		2 \$1850oz			\$215007	Share data Basic shares (m)	62.1	ED y	vith build	equity raise	76.6
10.0% disco		1,323	1,422	1,521	1,575	FD with options (m)	71.0	FDA	vitii bullu i	equity raise	/0.0
7.5% disco		1,323	1,422	1,699	1,762	Ratio analysis	CY18A	CY19A	CY20E	CY21E	CY228
5.0% disco		1,659	1,784	1,909	1,782		91.3	107.3	137.6	141.3	143.6
	-					Average shares out (m)	-	107.5	137.0	141.5	143.0
Ungeared project I Project NPV (C\$m)*		94% \$1850oz	\$195007	106%	105% \$2150oz	EPS (C\$/sh) CFPS (C\$/sh)	-	-	-	-	-
Project NPV (C\$m)* 3.7g/t Au	-	1,368	1,481				- 1,260.1	- 1,470.9	- 1,881.7	-	- 2,186.1
0.		-	· ·	1,594	1,707	EV (C\$m)	1,260.1	1,470.9		1,978.5	2,180
4.1g/t Au		1,659	1,784	1,909	1,984	FCF yield (%)	-	-	-	-	-
4.5g/t Au NPV5 (C\$m)*		1,949 \$1850oz	2,036	2,170	2,304	PER (x)	-	-	-	-	-
							-	-	-	-	-
Payability: 6 Payability: 7		1,368	1,481	1,594	1,707	EV/EBITDA (x)	-	-	-	-	- CV2.2
		1,659	1,784	1,909	1,984	Income statement	CY18A	CY19A	CY20E	CY21E	CY221
Payability: 8		1,949	2,036	2,170	2,304	Net revenue (C\$m)	-	-	-	-	-
*Project level NPV, excl finance co						Gross profit (C\$m)		- 0.4	-	-	-
Group valuation over time [*]	2021	2Q22	2Q23	2Q24	2Q25	D&A, attrib (C\$m)	0.2		-	-	-
Eskay Creek (C\$m)	1,392	1,493	1,721	1,858	1,524	Admin (C\$m)	4.3	4.5	5.0	5.0	5.0
Net cash prior qtr (C\$m)	85	(9)	(65)	(127)	265	Expensed exploration (C\$m)	11.5	12.8	-	-	-
G&A and finance costs (C\$m)	(84)	(83)	(80)	(68)	(50)	Finance cost (C\$m)	(0.0)	(0.1)	-	-	(3.3)
Cash from options (C\$m)	10	10	10	10	10	Royalty (C\$m)		-	-	-	-
Snip	61	61	61	61	61	Forex, other (C\$m)	(0.5)	9.5	-	-	-
NAV FF FD (C\$m)	1,465	1,473	1,648	1,735 22.65*	1,811	Taxes (C\$m)	-	-	-	-	-
1xNAV _{5%} /sh FF FD (C\$/sh) Equity ROI from spot (% pa)	20.62^	20.74^ 50%	21.52* 34%	22.05*	23.65*	Net income (C\$m) Cash flow, attrib.	(15.5) CY18A	(27.1) CY19A	(5.0) CY20E	(5.0)	(1.7) CY22E
Geared company NAV dilute	d for mine					EBIT (C\$m)	(15.5)	(27.2)	(5.0)	CY21E (5.0)	(5.0)
2Q22 1xNAV FF FD (C\$/sh)^		2 \$1850oz				Add back D&A (C\$m)	0.2	0.4	(5.0)	(3.0)	(5.0)
10.0% disco		16.82	18.25	19.68	20.45	Less tax + net interest (C\$m)	(0.0)	(0.1)	-	-	(3.3)
7.5% disco		18.48	20.04	21.60	22.49	Net change in wkg cap (C\$m)	(0.0)	4.2	-	-	(5.5)
5.0% disco		20.40	22.11	23.83		Add back other non-cash (C\$m)		12.0	-	-	-
Geared project I		85%	91%	97%	24.85 96%	Cash flow ops (C\$m)	1.6 (15.1)	(10.5)	(5.0)	(5.0)	(1.7)
2Q22 1xNAV FF FD (C\$/sh)^		\$1850oz				PP&E - build + sust. (C\$m)	3.2	0.6	-	(139.6)	(163.6
Payability: 6		16.38	17.92	19.46	21.00	PP&E - build + sust. (C\$III) PP&E - expl'n (C\$m)	-	(0.2)	-	(159.0) -	(105.0
Payability: 6 Payability: 7		20.40	22.11	23.83	24.85	Cash flow inv. (C\$m)	3.2	0.4	-	(139.6)	(174.8
Payability: 7 Payability: 8		24.43	25.60	23.83	24.85	Share issue (C\$m)	12.0	22.1	-	100.0	(1/4.0
Payability: 8 ^Project NPV incl grp SG&A & fin.						Proceeds from sale (C\$m)	12.U	22.1	-	100.0	-
Production	cost, +net ca Y1	rsn; *allute Y2				Debt draw (repay) (C\$m)	-	-		-	-
Gold production (000oz)	439	360	Y3 359	Y4 339	Y5 354	Cash flow fin. (C\$m)	- 12.0	22.1	-	70.6	141.2
C1 cost (US\$/oz)	439 810	360 880	359 844	339 831	354 815		0.1	12.0	- (5.0)	170.6 26.0	(35.2)
AISC cost (US\$/oz)	810	880 917	844 876	861	815	Net change in cash (C\$m) EBITDA (C\$m)	(15.4)	(26.8)	(5.0)	(5.0)	(35.2)
AISC COST (US\$/02) AISC = C1 + ug sustaining capex,			010	001	ورن	Balance sheet	(15.4) CY18A	(26.8) CY19A			(5.0) CY221
niae – ez + uy sustaininy capex,	, ⊥ = 1∠IVI LO I	JCL 2024				Cash (C\$m)	1.1	13.1	CY20E 23.9	CY21E 49.9	14.6
Gold prod'n (LF	iS, 000oz)		C (RHS, US	\$\$/oz Au)	1100/						14.6 5.2
500koz					1100/oz	Acc rec., inv, prepaid (C\$m) PP&E + other (C\$m)	3.7	2.8 8.5	5.2	5.2 152 0	5.2 328.5
400koz					1000/oz		19.7		14.2	153.8	
			7 [Total assets (C\$m)	24.6	24.4	43.3	208.9	348.4
300koz				→	900/oz	Debt (C\$m)	-	1.5	4.5	75.1	216.3
					800/oz	Accounts payable (C\$m)	1.4	4.1	11.8	11.8	11.8
200koz						Others (C\$m)	4.6	7.2	6.2	6.2	6.2
200koz											1217
200koz / / / / / / / / / / / / / / / / / / /					700/oz	Total liabilities (C\$m)	6.0	12.8	22.4	93.0	234.2
100koz						Sh'hlds equity + wrnts (C\$m)	81.6	99.2	131.2	231.2	231.2
200koz	Y3	Y4			700/oz 600/oz						

Source: SCP estimates





DISCLOSURES & DISCLAIMERS

This research report (as defined in IIROC Rule 3400) is issued and approved for distribution in Canada by Sprott Capital Partners LP ("SCP"), an investment dealer who is a member of the Investment Industry Regulatory Organization of Canada ("IIROC") and the Canadian Investor Protection Fund ("CIPF"). The general partner of SCP is Sprott Capital Partners GP Inc. and SCP is a wholly-owned subsidiary of Sprott Inc., which is a publicly listed company on the Toronto Stock Exchange under the symbol "SII". Sprott Asset Management LP ("SAM"), a registered investment manager to the Sprott Funds and is an affiliate of SCP. This research report is provided to retail clients and institutional investors for information purposes only. The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of SCP's research department. The information in this report is drawn from sources believed to be reliable but the accuracy or completeness of the information is not guaranteed, nor in providing it does SCP and/or affiliated companies or persons assume any responsibility or liability whatsoever. This report is not to be construed as an offer to sell or a solicitation of an offer to buy any securities. SCP accepts no liability whatsoever for any loss arising from any use or reliance on this research report or the information contained herein. Past performance is not a guarantee of future results, and no representation or warranty, expressed or implied, is made regarding future performance of any security mentioned in this research report. The price of the securities mentioned in this research report and the income they generate may fluctuate and/or be adversely affected by market factors or exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. Furthermore, the securities discussed in this research report may not be liquid investments, may have a high level of volatility or may be subject to additional and special risks associated with securities and investments in emerging markets and/or foreign countries that may give rise to substantial risk and are not suitable for all investors. SCP may participate in an underwriting of, have a position in, or make a market in, the securities mentioned herein, including options, futures or other derivatives instruments thereon, and may, as a principal or agent, buy or sell such products.

DISSEMINATION OF RESEARCH: SCP's research is distributed electronically through email or available in hard copy upon request. Research is disseminated concurrently to a pre-determined list of clients provided by SCP's Institutional Sales Representative and retail Investment Advisors. Should you wish to no longer receive electronic communications from us, please contact <u>unsubscribe@sprott.com</u> and indicate in the subject line your full name and/or corporate entity name and that you wish to unsubscribe from receiving research.

RESEARCH ANALYST CERTIFICATION: Each Research Analyst and/or Associate who is involved in the preparation of this research report hereby certifies that:

- The views and recommendations expressed herein accurately reflect his/her personal views about any and all of the securities or issuers that are the subject matter of this research report;
- His/her compensation is not and will not be directly related to the specific recommendations or view expressed by the Research analyst in this research report;
- They have not affected a trade in a security of any class of the issuer within the 30-day period prior to the publication of this research report;
- They have not distributed or discussed this Research Report to/with the issuer, investment banking group or any other third party except for the sole purpose of verifying factual information; and
- They are unaware of any other potential conflicts of interest.

UK RESIDENTS: Sprott Partners UK Limited ("Sprott") is an appointed representative of PillarFour Securities LLP which is authorized and regulated by the Financial Conduct Authority. This document has been approved under section 21(1) of the FMSA 2000 by PillarFour Securities LLP ("PillarFour") for communication only to eligible counterparties and professional clients as those terms are defined by the rules of the Financial Conduct Authority. Its contents are not directed at UK retail clients. PillarFour does not provide investment services to retail clients. PillarFour publishes this document as non-independent research which is a marketing communication under the Conduct of Business rules. It has not been prepared in accordance with the regulatory rules relating to independent research, nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. It does not constitute a personal recommendation and does not constitute an offer or a solicitation to buy or sell any security. Sprott and PillarFour consider this note to be an acceptable minor non-monetary benefit as defined by the FCA which may be received without charge. This is because the content is either considered to be commissioned by Sprott's clients as part of their advisory services to them or is short term market commentary. Neither Sprott nor PillarFour nor any of its directors, officers, employees or agents shall have any liability, howsoever arising, for any error or incompleteness of fact or opinion in it or lack of care in its preparation or publication; provided that this shall not exclude liability to the extent that this is impermissible under the law relating to financial services. All statements and opinions are made as of the date on the face of this document and are not held out as applicable thereafter. This document is intended for distribution only in those jurisdictions where PillarFour is permitted to distribute its research.

IMPORTANT DISCLOSURES FOR U.S. PERSONS: This research report was prepared by Sprott Capital Partners LP ("SCP"), a company authorized to engage in securities activities in Canada. SCP is not a registered broker/dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Sprott Global Resource Investments Ltd. ("SGRIL"), a broker dealer in the United States registered with the Securities Exchange Commission ("SEC"), the Financial Industry Authority ("FINRA"), and a member of the Securities Investor Protection Corporation ("SIPC"). Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SCP.

SGRIL accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor. The analyst whose name appears in this research report is not licensed, registered, or qualified as a research analyst with FINRA and may not be an associated person of SGRIL and, therefore, may not be subject to applicable restrictions under FINRA Rule 2241 regarding communications by a research analyst with a subject company, public appearances by the research analyst, and trading securities held by a research analyst account. To make further inquiries related to this report, United States residents should contact their SGRIL representative.



Equity Research

ANALYST CERTIFICATION / REGULATION AC: The analyst and associate certify that the views expressed in this research report accurately reflect their personal views about the subject securities or issuers. In addition, the analyst and associate certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

SPROTT CAPITAL PARTNERS EXPLANATION OF RECCOMENDATIONS: Should SCP issue research with recommendations, the research rating guidelines will be based on the following recommendations:

BUY: The stocks total returns are expected to be materially better than the overall market with higher return expectations needed for more risky securities markets

NEUTRAL: The stock's total returns are expected to be in line with the overall market

SELL: The stocks total returns are expected to be materially lower than the overall market

TENDER: The analyst recommends tendering shares to a formal tender offering

UNDER REVIEW: The stock will be placed under review when there is a significant material event with further information pending; and/or when the research analyst determines it is necessary to await adequate information that could potentially lead to a reevaluation of the rating, target price or forecast; and/or when coverage of a particular security is transferred from one analyst to another to give the new analyst time to reconfirm the rating, target price or forecast.

NOT RATED ((N/R): The stock is not currently rated

Re	search Disclosure	Response
1	SCP and its affiliates collectively beneficially owns 1% or more of any class of the issuer's equity securities ¹	YES
2	The analyst or any associate of the analyst responsible for the report or recommendation or any individual directly involved in the preparation of the report holds or is short any of the issuer's securities directly or through derivatives	NO
3	An SCP partner, director, officer or analyst involved in the preparation of a report on the issuer, has during the preceding 12 months provided services to the issuer for remuneration other than normal course investment advisory or trading execution services	NO
4	SCP has provided investment banking services for the issuer during the 12 months preceding the date of issuance of the research report or recommendation	YES
5	Name of any director, officer, employee or agent of SCP who is an officer, director or employee of the issuer, or who serves in an advisory capacity to the issuer	NO
6	SCP is making a market in an equity or equity related security of the issuer	NO
7	The analyst preparing this report received compensation based upon SCP's investment banking revenue for the issuer	NO
8	The analyst has conducted a site visit and has viewed a major facility or operation of the issuer	NO
9	The analyst has been reimbursed for travel expenses for a site visit by the issuer	NO

Sprott Capital Partners Equity Research Ratings:

Summary of recommendations as of July 2021	
BUY:	44
HOLD:	0
SELL:	0
UNDER REVIEW:	0
TENDER:	0
NOT RATED:	0
TOTAL	44

¹ As at the end of the month immediately preceding the date of issuance of the research report or the end of the second most recent month if the issue date is less than 10 calendar days after the end of the most recent month

